Beam Therapeutics

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

Shots: Beam to receive $50M up front and $25M as near-term milestones & will be eligible to receive other milestones along with royalties on sales, following the exercise of the option. The companies will work on 6 research programs focusing on C3 & other complement targets in the eye, liver, and brain Apellis holds exclusive …

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases Read More »

Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope

Fresh off its first FDA approval, Apellis Pharmaceuticals is teaming up with Beam Therapeutics, a partnership that will use Beam’s base-editing technology to develop new therapies for complement system disorders. Apellis has committed to pay Beam $75 million to kick off the alliance.

Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver

Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.